VS 8

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

VS 8 

VS 8 (Compound VS 8) 是一种有效的口服 VEGFR-2 抑制剂,具有显著的抗血管生成 (anti-angiogenic) 作用。 VS 8 诱导癌细胞凋亡 (apoptosis) 和迁移。 VS 8 对 CSCs (癌症干细胞)有活性。

VS 8

VS 8 Chemical Structure

CAS No. : 2471865-38-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

VS 8 (Compound VS 8) is a potent, orally active VEGFR-2 inhibitor with significant anti-angiogenic effects. VS 8 induces cancer cell apoptosis and migration. VS 8 is active against CSCs (Cancer stem cells)[1].

IC50 & Target

VEGFR-2

 

体外研究
(In Vitro)

VS 8 (Compound VS 8) (0.01-100 µM, 24 h) shows potent anti-proliferative activity against MCF-7, MDA-MB-231, Hep G2, and HUVECs cells[1].
VS 8 induces early apoptosis in MDA-MB-231 (1413 nM, 72 h), Hep G2 (257.80 nM, 24 h), and HUVECs (1954 nM, 24 h) cells[1].
VS 8 is shown to be a pro-oxidant molecule that enhances the ROS level in Hep G2 cells[1].
VS 8 inhibits wound healing and migration of MCF-7 cancer cells[1].
VS 8 downregulates human vascular endothelial growth factor (hVEGF) and hVEGFR-2 expression in HUVECs[1].
VS 8 (257.80 nM, 48 h) arrests cell cycle at ‘G0/G1’ and ‘S’ phase in CD44+ and CD133+ CSCs, respectively[1].
VS 8 inhibits TGF-β-induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma by the upregulation of E-cadherin and the suppression of vimentin and SNAIL[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: MCF-7, MDA-MB-231, Hep G2, and HUVECs cells
Concentration: 0.01, 0.1, 1, 10, 50, and 100 µM
Incubation Time: 24 h
Result: Showed significantly potent anti-proliferative activity against all the selected cell lines in a dose-dependent manner, with IC50 values of 953.30, 1413, 257.80, and 1954 nM against MCF-7, MDA-MB-231, Hep G2, and HUVECs cells.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231, Hep G2, and HUVECs cells
Concentration: 1413, 257.80, and 1954 nM for MDA-MB-231, Hep G2, and HUVECs cells, respectively.
Incubation Time: 72 h for MDA-MB-231 cells; 24 h for Hep G2 and HUVECs cells
Result: Resulted in high population of early apoptotic MDA-MB-231 cells (68.34 ± 0.18%). A significant increase in % apoptotic index (~86.66%) was observed in Hep G2 cells. The percentage of early apoptotic cells were found to be ~37.53% in HUVECs cells.

Cell Cycle Analysis[1]

Cell Line: CD44+ and CD133+ CSCs isolated from Hep G2 cells
Concentration: 257.80 nM
Incubation Time: 48 h
Result: Arrested cell cycle at ‘G0/G1’ and ‘S’ phase in CD44+ and CD133+ CSCs, respectively.

体内研究
(In Vivo)

VS 8 inhibits angiogenesis in the chick chorioallantoic membrane without oral toxicity[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (180-220 gm)[1]
Dosage: 5 mg/kg
Administration: Oral administration (Pharmacokinetic Analysis)
Result: Pharmacokinetic parameters for VS 8 in rats after administration of oral dose (5 mg/ kg) [1]

Pharmacokinetic parameters Unit Value
Cmax μg/mL 39.7193 ± 0.36
Tmax hrs 6 ± 0
AUC(0-72) mg/mL*hrs 621.3236 ± 1.843
AUC(0-∞) mg/mL*hrs 625.2219 ± 1.864
AUMC(0-∞) (mg/mL*hrs2) 8929.284 ± 72.85
MRT hrs 14.2817 ± 0.102
t1/2 hrs 11.9277 ± 0.324


Data represented as mean ± SD (n = 3); t1/2, Half-Life; Cmax, Maximum Observed Concentration; Tmax, Maximum Observed Time; AUC, Area Under Curve; AUMC Area Under Movement Curve, MRT, Mean Residence Time.

分子量

479.45

Formula

C26H20F3N3O3

CAS 号

2471865-38-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Siddharth J Modi, et al. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Eur J Med Chem. 2020 Dec 1;207:112851.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务